Saturday 10 October 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
1
Average plausibility
70%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
RegionAllGlobalAfricaNorth AmericaSouth AmericaAsia-PacificEuropeMiddle East
TopicAllPoliticsConflict & SecurityBusinessScienceHealth
01HealthAsia-Pacific

Australian advocates seek subsidised weight-loss drugs for women with PMOS

The Guardian reports an access campaign alongside off-label prescribing of GLP-1 medicines.

Australian advocates say women with PMOS should receive subsidised weight-loss drugs, the Guardian reports. Its summary says GLP-1 medicines are being prescribed off-label because they are not specifically approved by the TGA to treat the condition.

What holds up

  • ✓The item reports an advocacy demand, not an announced subsidy decision.
  • ✓The summary explicitly distinguishes off-label prescribing from specific TGA approval for the condition.

What doesn't yet

  • ?The supplied extract does not identify the advocates or provide evidence of treatment benefits and risks.
  • ?It gives no patient numbers, costs or regulator response, and does not expand the term PMOS.

Ask before you share

  • →What clinical evidence supports these medicines for the condition?
  • →What eligibility, costs and safeguards would the proposed subsidy involve?

Sources & original reporting

  1. [1]The Guardian · Published 9 Oct 2026 · theguardian.com